C12N 2720/12232
Use of virus as therapeutic agent, other than vaccine
Official title: Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
C12N2720/12232 (Use of virus as therapeutic agent, other than vaccine) appears on 47 US grants and 59 published applications in this corpus.
Search patents in C12N- Granted patents
- 47
- Published applications
- 59
- Assignees
- 14
- Inventors
- 38
- Latest grant
- 13 May 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2000 | 2 | 0 |
| 2001 | 1 | 2 |
| 2002 | 2 | 6 |
| 2003 | 2 | 3 |
| 2004 | 2 | 5 |
| 2005 | 0 | 5 |
| 2006 | 3 | 3 |
| 2007 | 6 | 1 |
| 2008 | 3 | 8 |
| 2009 | 2 | 5 |
| 2010 | 6 | 2 |
| 2011 | 3 | 3 |
| 2012 | 1 | 3 |
| 2013 | 1 | 1 |
| 2014 | 3 | 1 |
| 2015 | 1 | 2 |
| 2016 | 0 | 0 |
| 2017 | 1 | 1 |
| 2018 | 2 | 2 |
| 2019 | 2 | 0 |
| 2020 | 2 | 1 |
| 2021 | 0 | 1 |
| 2022 | 1 | 0 |
| 2023 | 0 | 2 |
| 2024 | 0 | 2 |
| 2025 | 1 | 0 |
By publication year. Applications have been published since 2001.
Recent patents
- Oncolytic reovirus13 May 2025US 12,295,977 B2
- Reoviruses having modified sequences15 Feb 2022US 11,246,930 B2Oncolytics Biotech Inc.
- Attenuated reovirus2 Jun 2020US 10,668,119 B2Virocure, Inc.
- Reoviruses having modified sequences24 Mar 2020US 10,596,260 B2Oncolytics Biotech Inc.
- Generation of antibodies to tumor antigens and generation of tumor specific complement dependent cytotoxicity by administration of oncolytic vaccinia virus8 Oct 2019US 10,434,169 B2Sillajen Biotherapeutics, Inc.
- Immune Cell Fusion (ICF) and Uses Thereof5 Sep 2024US 2024/0293462 A1Trustees of Boston University
- Novel modified reovirus and use thereof8 Feb 2024US 2024/0041959 A1Virocure, Inc.
- Pharmaceutical composition for preventing or treating cancer3 Aug 2023US 2023/0241141 A1Virocure, Inc.
- Composition for preventing or treating inflammatory diseases of digestive system or colitis, comprising reovirus as active ingredient1 Jun 2023US 2023/0165916 A1Virocure, Inc.
- Improved Oncolytic Reovirus14 Jan 2021US 2021/0008136 A1
Most cited
By later US patents
- Reovirus for the treatment of cellular proliferative disorders56US 6,136,307 AOncolytics Biotech Inc. · 2000
- Reovirus for the treatment of neoplasia46US 6,110,461 AOncolytics Biotech Inc. · 2000
- Reovirus for the treatment of neoplasia22US 6,261,555 B1Oncolytics Biotech Inc. · 2001
- Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders22US 6,565,831 B1Oncolytics Biotech Inc. · 2003
- Reovirus for the treatment of neoplasia20US 6,344,195 B12002